MEMBRANE DYNAMICS AND FUNCTIONAL EFFECTS ON MYELOMA CELLS AFTER DARATUMUMAB TREATMENT

被引：0
|
作者：
Yakymiv, Y. [1 ]
Faini, A. C. [1 ]
Castella, B. [1 ]
Morandi, F. [1 ]
Larocca, A. [1 ]
Oliva, S. [1 ]
Horenstein, A. L. [1 ]
Massaia, M. [1 ]
Malavasi, F. [1 ]
机构：
[1] Dipartimento Sci Med, Lab Immunogenet, Turin, Italy
来源：
HAEMATOLOGICA | 2018年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
CO095
引用
收藏
页码：S66 / S66
页数：1
相关论文
共 50 条
  • [1] Induction of structural and functional effects of myeloma cells after daratumumab treatment
    Castella, Barbara
    Faini, Angelo C.
    Yakymiv, Yuliya
    Morandi, Fabio
    Larocca, Alessandra
    Oliva, Stefania
    Horenstein, Alberto L.
    Massaia, Massimo
    Malavasi, Fabio
    CANCER RESEARCH, 2018, 78 (13)
  • [2] Multinucleated giant myeloma cells after failure of daratumumab therapy
    Guijarro, Francisca
    Rozman, Maria
    Matutes, Estella
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 (04) : 432 - 432
  • [3] Daratumumab for the Treatment of Multiple Myeloma
    Plesner, Torben
    Krejcik, Jakub
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [4] Daratumumab for the treatment of multiple myeloma
    Touzeau, Cyrille
    Moreau, Philippe
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (07) : 887 - 893
  • [5] Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells
    Chillemi, Antonella
    Quarona, Valeria
    Zito, Andrea
    Morandi, Fabio
    Marimpietri, Danilo
    Cuccioloni, Massimiliano
    Robert, Oldham J.
    Mark, Cragg S.
    Bolzoni, Marina
    Toscani, Denise
    Pistoia, Vito
    Giuliani, Nicola
    Horenstein, Alberto L.
    Sasser, Kate
    Malavasi, Fabio
    BLOOD, 2015, 126 (23)
  • [6] Daratumumab for the treatment of multiple myeloma
    Goldsmith, S. R.
    Foley, N.
    Schroeder, M. A.
    DRUGS OF TODAY, 2021, 57 (10) : 591 - 605
  • [7] The safety of daratumumab for the treatment of multiple myeloma
    Cejalvo, Maria J.
    Ribas, Paz
    de la Rubia, Javier
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (06) : 753 - 760
  • [8] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
    David S. Siegel
    Gary J. Schiller
    Christy Samaras
    Michael Sebag
    Jesus Berdeja
    Siddhartha Ganguly
    Jeffrey Matous
    Kevin Song
    Christopher S. Seet
    Giampaolo Talamo
    Mirelis Acosta-Rivera
    Michael Bar
    Donald Quick
    Bertrand Anz
    Gustavo Fonseca
    Donna Reece
    William E. Pierceall
    Weiyuan Chung
    Faiza Zafar
    Amit Agarwal
    Nizar J. Bahlis
    Leukemia, 2020, 34 : 3286 - 3297
  • [9] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
    Siegel, David S.
    Schiller, Gary J.
    Samaras, Christy
    Sebag, Michael
    Berdeja, Jesus
    Ganguly, Siddhartha
    Matous, Jeffrey
    Song, Kevin
    Seet, Christopher S.
    Talamo, Giampaolo
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald
    Anz, Bertrand
    Fonseca, Gustavo
    Reece, Donna
    Pierceall, William E.
    Chung, Weiyuan
    Zafar, Faiza
    Agarwal, Amit
    Bahlis, Nizar J.
    LEUKEMIA, 2020, 34 (12) : 3286 - 3297
  • [10] Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients
    Hojholt, Karen Louise
    Gregersen, Henrik
    Szabo, Agoston Gyula
    Klausen, Tobias Wirenfeldt
    Levring, Mette Boegh
    Preiss, Birgitte
    Helleberg, Carsten
    Breinholt, Marie Fredslund
    Hermansen, Emil
    Rahbek Gjerdrum, Lise Mette
    Bonlokke, Soren Thorgaard
    Nielsen, Katrine
    Kjeldsen, Eigil
    Iversen, Katrine Fladeland
    Teodorescu, Elena Manuela
    Kurt, Eva
    Strandholdt, Casper
    Andersen, Mette Klarskov
    Vangsted, Annette Juul
    HEMATOLOGICAL ONCOLOGY, 2021, 39 (04) : 521 - 528
12345